Pre-clinical assessment of novel multivalent msp3 malaria vaccine constructs

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Bang, Gilles ^a   Prieur, Eric ^a   Roussilhon, Christian ^a   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3 VACCINE; UNCLASSIFIED DRUG; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MALARIA; MALARIA CONTROL; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; SENEGAL; VACCINE PRODUCTION; WESTERN BLOTTING; ADOLESCENT; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; C57BL MOUSE; CHILD; CROSS REACTION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNIZATION; IMMUNOLOGY; INFANT; MALARIA FALCIPARUM; METABOLISM; PARASITOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 82455174360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028165     Document Type: Article

References (36)

1. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
2. Huber W, Felger I, Matile H, Lipps HJ, Steiger S, et al. (1997) Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 87: 231-234.
3. McColl DJ, Anders RF, (1997) Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 90: 21-31.
4. Audran R, Cachat M, Lurati F, Soe S, Leroy O, et al. (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73: 8017-8026.
5. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2: e344.
6. Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, et al. (2004) Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 190: 1010-1018.
7. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, et al. (2007) Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25: 2723-2732.
8. Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, et al. (2009) Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J 8: 163.
9. Sirima SB, Cousens S, Druilhe P, (2011) Protection against malaria by MSP3 candidate vaccine. N Engl J Med 365: 1062-1064.
10. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, et al. (2007) Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 4: e320.
11. Singh S, Soe S, Weisman S, Barnwell JW, Perignon JL, et al. (2009) A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One 4: e5410.
12. Demanga CG, Daher LJ, Prieur E, Blanc C, Perignon JL, et al. (2010) Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect Immun 78: 486-494.
13. Daher LJ, Demanga CG, Prieur E, Perignon JL, Bouharoun-Tayoun H, et al. (2010) Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models. Infect Immun 78: 477-485.
14. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Benmohamed L, et al. (1994) Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 153: 190-204.
15. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, et al. (2000) Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6: 1258-1263.
16. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, et al. (2007) Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One 2: e645.
17. Fontenille D, Lochouarn L, Diatta M, Sokhna C, Dia I, et al. (1997) Four years' entomological study of the transmission of seasonal malaria in Senegal and the bionomics of Anopheles gambiae and A. arabiensis. Trans R Soc Trop Med Hyg 91: 647-652.
18. Zwetyenga J, Rogier C, Spiegel A, Fontenille D, Trape JF, et al. (1999) A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Trans R Soc Trop Med Hyg 93: 375-380.
19. Rogier C, Tall A, Diagne N, Fontenille D, Spiegel A, et al. (1999) Plasmodium falciparum clinical malaria: lessons from longitudinal studies in Senegal. Parassitologia 41: 255-259.
20. Druilhe P, Bouharoun-Tayoun H, (2002) Human antibody subclass ELISA. Methods Mol Med 72: 457-459.
21. Druilhe P, Khusmith S, (1987) Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun 55: 888-891.
22. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P, (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
23. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 178: 3099-3106.
24. Jouin H, Daher W, Khalife J, Ricard I, Puijalon OM, et al. (2004) Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry. Cytometry A 57: 34-38.
25. Duah NO, Miles DJ, Whittle HC, Conway DJ, (2010) Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol 32: 125-134.
26. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. (2008) Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 76: 759-766.
27. Martin RM, Brady JL, Lew AM, (1998) The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212: 187-192.
28. Martin RM, Silva A, Lew AM, (1997) The Igh-1 sequence of the non-obese diabetic (NOD) mouse assigns it to the IgG2c isotype. Immunogenetics 46: 167-168.
29. Morgado MG, Cam P, Gris-Liebe C, Cazenave PA, Jouvin-Marche E, (1989) Further evidence that BALB/c and C57BL/6 gamma 2a genes originate from two distinct isotypes. EMBO J 8: 3245-3251.
30. Seppala I, Sarvas H, Peterfy F, Makela O, (1981) The four subclasses of IgG can be isolated from mouse serum by using Protein A-Sepharose. Scand J Immunol 14: 335-342.
31. Foth BJ, Zhang N, Mok S, Preiser PR, Bozdech Z, (2008) Quantitative protein expression profiling reveals extensive post-transcriptional regulation and post-translational modifications in schizont-stage malaria parasites. Genome Biol 9: R177.
32. Snapper CM, Paul WE, (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
33. Snapper CM, Hornbeck PV, Atasoy U, Pereira GM, Paul WE, (1988) Interleukin 4 induces membrane Thy-1 expression on normal murine B cells. Proc Natl Acad Sci U S A 85: 6107-6111.
34. Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K, (1997) Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci U S A 94: 3948-3953.
35. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297-308.
36. Singh S, Soe S, Roussilhon C, Corradin G, Druilhe P, (2005) Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infect Immun 73: 1235-1238.